These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 17545388)

  • 1. Drug pricing in pediatrics: the egregious example of indomethacin.
    Jobe AH
    Pediatrics; 2007 Jun; 119(6):1197-8. PubMed ID: 17545388
    [No Abstract]   [Full Text] [Related]  

  • 2. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Web site provides pediatric vaccine pricing.
    Manag Care; 2008 Oct; 17(10):48. PubMed ID: 18990925
    [No Abstract]   [Full Text] [Related]  

  • 4. Applications of two-part pricing in pharmaceutical markets.
    Civan A
    Health Aff (Millwood); 2008; 27(6):1749-50. PubMed ID: 18997242
    [No Abstract]   [Full Text] [Related]  

  • 5. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
    Zaric GS
    Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-18. PubMed ID: 18345557
    [No Abstract]   [Full Text] [Related]  

  • 9. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 10. Two ideas to increase innovation and reduce pharmaceutical costs and prices.
    Jayadev A; Stiglitz J
    Health Aff (Millwood); 2009; 28(1):w165-8. PubMed ID: 19088104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of privatization of the drug distribution system on drug prices in Malaysia.
    Babar ZD; Izham MI
    Public Health; 2009 Aug; 123(8):523-33. PubMed ID: 19665741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical industry in pediatric drug development: partners and collaborators with academia and the FDA.
    Mulberg AE
    J Pediatr Gastroenterol Nutr; 2008 Nov; 47(5):711-3. PubMed ID: 18955888
    [No Abstract]   [Full Text] [Related]  

  • 13. [Children on the drug development map. The Danish Society of Clinical Pharmacology].
    Thirstrup S; Heisterberg J;
    Ugeskr Laeger; 2008 Mar; 170(12):1039. PubMed ID: 18397657
    [No Abstract]   [Full Text] [Related]  

  • 14. Funding pharmaceutical innovation through direct tax credits.
    Lybecker KM; Freeman RA
    Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug development for children: how is pharma tackling an unmet need?
    Hawcutt DB; Smyth RL
    IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The philosophy of drug firms on drug pricing].
    Jolidon RM
    Rev Med Suisse; 2008 May; 4(159):1358-60. PubMed ID: 18592729
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug expenditure in Ireland 1997-2007.
    Barry M; Molloy D; Usher C; Tilson L
    Ir Med J; 2008; 101(10):299-302. PubMed ID: 19205138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug industry in India is threatened by free trade agreement].
    Jeppsson A
    Lakartidningen; 2009 Oct 7-13; 106(41):2589. PubMed ID: 19927922
    [No Abstract]   [Full Text] [Related]  

  • 20. [The therapeutic orphan--end of an era?].
    Gorodischer R
    Harefuah; 1998 Dec; 135(12):601-2. PubMed ID: 10911492
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.